Osteopontin: A novel inflammatory mediator of cardiovascular disease

Frontiers in Bioscience

Volumn 12, Issue 1, 2007, Pages 214-221

  Singh, Mahipal ^a   Ananthula, Srinivas ^a   Milhorn, Denise M ^a   Krishnaswamy, Guha ^a   Singh, Krishna ^a,b  

^a East Tennessee State University   (United States)

^b James H Quillen VA Medical Center   (United States)

Author keywords

Coronary artery disease; Left ventricular hypertrophy; Myocardial infarction; Myocardial remodeling; Osteopontin; Valvular calcification; Vascular inflammation

Indexed keywords

EID: 34249031626     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2059     Document Type: Article

References (72)

1. A. O'Regan: The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 14, 479-488 (2003)
2. M. Mazzali, T. Kipari, V. Ophascharoensuk, J. A. Wesson, R. Johnson, & J. Hughes: Osteopontin-a molecule for all seasons. QJM. 95, 3-13 (2002)
3. D. T. Denhardt & X. Guo: Osteopontin: a protein with diverse functions. FASEB J. 1, 1475-1482 (1993)
4. T. Uede, Y. Katagiri, J. lizuka, & M. Murakami: Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein? Microbiol. Immunol. 41, 641-648 (1997)
5. C. M. Giachelli:. Ectopic calcification: new concepts in cellular regulation. Z.Kardiol. 90 (Suppl 3), 31-37 (2001)
6. S. Jono, C. Peinado, & C. M. Giachelli,C.M: Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J.Biol.Chem. 275, 20197-20203 (2000)
7. K. J. Bayless, G. A. Meininger, J. M. Schdtz, & G. E. Davis:. Osteopontin is a ligand for the alpha4betal integral. J. Cell Sci 111 (Pt9), 1165-1174(1998)
8. C. Giachelli, N. Bae, D. Lombardi, M. Majesky, & S. Schwarte Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cefl phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biodiem.Bicphys.Res. Commun. 177, 867-873 (1991)
9. D. L. Myers, K. J. Harmon, V. Lindner, & L. Liaw: Alterations of arterial physiology in osteopontin-null mice. Arteriosder.Thmmb.VascBid. 23, 1021-1028 (2003)
10. S. Stromblad, J.C. Becker, M. Yebra, P.C. Brooks & D.A. Cheresh: Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin.Invest 98:426-433 (1996)
11. C.M. Storgard, D.O. Stupack, A. Jonczyk, S.L.Goodman, R.I. Fox & D.A. Cheresh: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin. Invest 103:47-54 (1999)
12. D.R. Senger, S.R. Ledbetter, K.P. Claffey, A. Papadopoulos-Sergiou, C.A. Peruzzi & M. Detmar: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol. 149:293-305 (1996)
13. N. Shijubo, T. Uede, S. Kon, M. Maeda, T. Segawa, A. Imada, M. Hirasawa & S. Abe: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir.Crit Care Med. 160:1269-1273(1999)
14. F. Takahashi, S. Akutagawa, H. Fukumoto, S. Tsukiyama, Y. Ohe, K. Takahashi, Y. Fukuchi, N. Saijo & K. Nishio.K: Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int.J Cancer 98:707-712 (2002)
15. Y. Asou, S.R. Rittling, H.Yoshitake, K. Tsuji, K. Shinomiya, A. Nifuji, D.T. Denhardt & M. Noda: Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142:1325-1332 (2001)
16. D. Leali, P. Dell'Era, H. Stabile, B. Sennino, A.F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti,D & M. Presta. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171:1085-1093 (2003)
17. R. Ross: Atherosclerosis is an inflammatory disease. Am.Heart J. 138:8419-8420 (1999)
18. D. Bruemmer, A. R. Collins, G. Noh, W. Wang, M. Territo, S. Arias-Magallona, M. C. Fishbein. F. Blaschke. U. Kintscher, K. Graf, R. E. Liaw & W. A. Hsueh: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112, 1318 -1331 (2003)
19. A. Strom, A. Franzen, C. Wangnerud, A. K. Knutsson, D. Heinegard, & A. Hultgardh-Nilsson: Altered vascular remodeling in osteopontin-deficient atherosclerotic mice. J Vasc.Res. 41:314-322 (2004)
20. C.M. Giachelli, D. Lombardi, R.J. Johnson, C.E. Murry & M. Almeida: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 152:353-358 (1998)
21. S. Ashkar, G.F.Weber, V. Panoutsakopoulou, M.E. Sanchirico, M. Jansson, S. Zawaideh, S.R. Rittling, D.T. Denhardt, M.J. Glimcher, & H. Cantor: 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864 (2000)
22. J.Y. Tian, E.S. Sorensen, W.T. Butler, C.A. Lopez, M.S. Sy, N.K. Desai, & D.T. Denhardt. Regulation of no synthesis induced by inflammatory mediators in RAW264.7 cells: collagen prevents inhibition by osteopontin. Cytokine 12:450-457 (2000).
23. K. Singh, J. L. Balligand, T.A. Fischer, T. W. Smith & R. A. Kelly: Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J. Biol. Chem. 270, 28471-28478 (1995).
24. H. Guo, C. Q. Cai, R.A. Schroeder & P. C. Kuo,P.C: Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J. Immunol. 166, 1079-1086 (2001)
25. T. Wada, M. D. McKee, S. Steitz & C. M. Giachelli: Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ.Res. 84, 166-178 (1999)
26. C. C. Canver, R. D. Gregory, S. D. Cooler & M. C. Voytovich: Association of osteopontin with calcification in human mitral valves. J. Cardiovasc.Surg.(Torino) 41, 171-174 (2000).
27. S. S. Srivatsa, P. J. Harrity, P. B. Maercklein, L. Kleppe, J. Veinot, W. D. Edwards, C. M. Johnson, & L. A. Fitzpatrick: Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J.Clin.Invest 99, 996-1009 (1997)
28. K. Singh, D. Deonarine, V. Shanmugam, D. R. Senger, A. B. Mukherjee, P. L. Chang, C. W. Prince & B. B. Mukherjee: Calcium-binding properties of osteopontin derived from non-osteogenic sources. J.Biochem. (Tokyo) 114, 702-707 (1993)
29. L. A. Fitzpatrick, R. T. Turner & E. R. Ritman: Endochondral bone formation in the heart: a possible mechanism of coronary calcification. Endocrinology 144, 2214-2219 (2003)
30. R. Ohmori, Y. Momiyama, H. Taniguchi, R. Takahashi, M. Kusuhara, H. Nakamura & F. Ohsuzu: Plasma Osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170, 333-337 (2003)
31. V. Lesauskaite, P. Tanganelli, C. Sassi, E. Neri, F. Diciolla, L. Ivanoviene, M. C. Epistolato, A. V. Lalinga, C. Alessandrini & D. Spina: Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum.Pathol. 32, 1003-1011 (2001)
32. K. D. O'Brien, J. Kuusisto, D. D. Reichenbach, M. Ferguson, C. Giachelli, C. E. Alpers & C. M. Otto: Osteopontin is expressed in human aortic valvular lesions. Circulation 92, 2163-2168 (1995)
33. N. M. Rajamannan, M. Subramaniam, D. Rickard, S.R. Stock, J. Donovan, M. Springen, T. Orszulak, D. A. Fullerton, A. J. Tajik, R.O. Bonow &T. Spelsberg Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107, 2181-2184 (2003)
34. M. Shen, P. Marie, D. Farge, S. Carpentier, C. De Pollak, M. Hott, L. Chen, B. Martinet & A. Carpentier: Osteopontin is associated with bioprosthetic heart valve calcification in humans. C.R.Acad.Sci.III 320, 49-57 (1997)
35. E. R. Mohler III, L. P. Adam, P. McClelland, L. Graham & D. R. Hathaway: Detection of osteopontin in calcified human aortic valves. Arterioscler. Thromb. Vasc. Biol. 17, 547-552 (1997)
36. A. Bini, K. G. Mann, B. J. Kudryk & F. J. Schoen. Noncollagen bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler.Thromb. Vasc.Biol. 19, 1852-1861 (1999)
37. S.A. Steitz, M. Y. Speer, M. D. McKee, L. Liaw, M. Almeida, H. Yang & C. M. Giachelli: Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.Am.J.Pathol. 161, 2035-2046 (2002)
38. N. M. Rajamannan, M. Subramaniam, M. Springett, T.C. Sebo, M. Niekrasz, J. P. McConnell, R. J. Singh, N. J. Stone, R. O. Bonow & T.C. Spelsberg. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105, 2660-2665 (2002)
39. L. M. Wiester & C. M. Giachelli: Expression and function of the integrin alpha9betal in bovine aortic valve interstitial cells. J.Heart Valve Dis. 12, 605-616 (2003)
40. J. L. Cuy, B. L. Beckstead, C. D. Brown, A. S. Hoffman & C. M. Giachelli: Adhesive protein interactions with chitosan: consequences for valve endothelial cell growth on tissue-engineering materials. J.BiomedMater.Res. 67A, 538-547 (2003)
41. Atlas of heart failure: Cardiac function and dysfunction second edition. W.S. Colucci (ed) and E. Braunwald (series editor). (1999)
42. E.B. Williams, I. Halpert, S. Wickline, G. Davison, W. C. Parks & J. N. Rottman: Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation 92, 705-709 (1995)
43. K. Singh, G. Sirokman, C. Communal, K. G. Robinson, C. H. Comad, W. W. Brooks, O. H. Bing & W. S. Colucci: Myocaidial Osteopontin expression coincides wilh the development of heart failure. Hypertension 33, 663-670 (1999)
44. K. Graf, Y. S. Do, N. Ashizawa, W. P. Median, C. M.Giachelli, C. C. Maiboe, E. Fleck & W. A. Hsueh: Myocaidial Osteopontin expression is associated with left ventricular hypertrophy, Circulation 96, 3063-3071 (1997)
45. Z. Xie, M. Singh & K. Singh: Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 44, 826-831 (2004)
46. P. Stawowy, F. Blaschke, P. Pfautsch, S.Goetze, F. Lippek, B. Wollert-Wulf, E. Fleck & K. Graf: Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J. Heart Fail 4, 139-146 (2002)
47. M. Mavroidis & Y. Capetanaki: Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient caidiomyopathy. AmJ.Pathol. 160, 943-952 (2002)
48. M. T. Kaartinen, A. Pirhonen, A. Limala-Kankkunen & P. H. Maenpaa: Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties. J.Biol.Chem. 274, 1729-1735 (1999)
49. K. Singh, M. W. DeVouge & B. B. Mukherjee: Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated foims of osteopontin secreted by normal rat kidney cells. J.Biol.Chem. 265, 18696-18701 (1990)
50. N. A. Truebfood, Z. Xie, C. Communal, F. Sam, S. Ngoy, L. Liaw, A. W. Jenkins, J. Wang, D. B. Sawyer, O. H. Bing C. S. Apstein, W. S. Colucci and K. Singh: Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ.Res. 88, 1080-1087 (2001)
51. C. E. Murry, C. M. Giachelli, S. M. Schwarte & R. Vracko: Macrophages express osteopontin during repair of myocardial necrosis. AmJ.Pathol. 145, 1450-1462 (1994)
52. I. Komatsubara, T. Murakami, S. Kusachi, K. Nakamura, S. Hirohata, J. Hayashi, S. Takemoto, C. Suezawa, Y. Ninomiya & Y. Shiratori: Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc.PathoI. 12, 186-194 (2003)
53. H. Hanawa, S. Abe, M. Hayashi, T. Yoshida, K. Yoshida, T. Shiono, K. Fuse, M. Ito, H. Tachikawa, T. Kashimura T. Y. Okura, K. Kato, M. Kodama, S. Maruyama, T. Yamamoto & Y. Aizawa: Time course of gene expression in rat experimental autoimmune myocarditis. Clin.Sci.(Lond) 103, 623-632 (2002)
54. A. Tamura, M. Shingai, N. Aso, T. Hazuku & M. Nasu: Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. CircJ. 67, 742-744 (2003)
55. J. Hou, H. Kato, R.A. Cohen, A. V. Chobanian & P. Brecher: Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J.Clin.Invest96, 2469-2477 (1995)
56. B. I. Jugdutt, A. Lucas & M. I. Khan: Effect of angiotensin- converting enzyme inhibition on infarct collagen deposition and remodelling during healing after transmural canine myocardial infarction. Can.J.Cardiol. 13, 657-668 (1997)
57. K. Ono, A. Matsumori, T. Shioi, Y. Furukawa & S. Sasayama: Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98, 149-156 (1998)
58. P. Yue, B. M. Massie, P.C. Simpson & C. S. Long: Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am.J.Physiol 275, H250-H258 (1998)
59. Z. Xie, M. Singh, D. A. Siwik, W. L. Joyner & K. Singh: Osteopontin inhibits interleukin-1 beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: role of protein kinase C-zeta. J.Biol.Chem. 278, 48546-48552 (2003)
60. D.A. Siwik, D. L. Chang & W. S. Colucci: InterleukinIbeta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ.Res. 86, 1259-1265 (2000)
61. R. Agnihotri, H.C. Crawford, H. Haro, L.M. Matrisian, M.C. Havrda & L. Liaw: Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol.Chem. 276:28261-28267 (2001)
62. P. Hou, T. Troen, M.C. Ovejero, T. Kirkegaard, T.L. Andersen, I. Byrjalsen, M. Ferreras, T. Sato, S.D. Shapiro, N.T. Foged & J.M. Delaisse: Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 34:37-47 (2004)
63. W. A. Hsueh, Y. S. Do & R. Jeyaseelan: Angiotensin II and cardiac remodeling. Mt.Sinai J.Med. 65, 104-107 (1998)
64. N. Ashizawa, K. Graf, Y. S. Do, T. Nunohiro, C. M. Giachelli, W. P. Meehan, T. L. Tuan & W. A. Hsueh: Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J.CHn.Invest 98, 2218-2227 (1996)
65. Z. Xie, M. Singh & K. Singh: ERK1/2 and JNKs, but not p38 kinase, are involved h reactive oxygen speciesmediated induction of osteopontin gene expression by angiotensin II and interleukin-lbeta in adult rat cardiac fibroblasts. J.Cell Physiol 198, 399-407 (2004)
66. R. Rocha, C. L. Martin-Berger, P. Yang, R. Scherrer, J. Delyani & E. McMahon: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143, 4828-4836 (2002)
67. R. Rocha, A. E. Rudolph, G. E. Frierdich, D. A. Nachowiak, B. K. Kekec, E. A. Blomme, E. G. McMahon & J. A. Delyani: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am.J.Physiol Heart Circ.Physiol 283, H1802-H1810 (2002)
68. M. J. Young, L. Moussa, R. Dilley & J. W. Funder: Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144, 1121-1125 (2003)
69. A. R. Collins, J. Schnee, W. Wang, S. Kim, M. C. Fishbein, D. Bruemmer, R. E. Law, S. Nicholas, R. S. Ross & W. A. Hsueh: Osteopontin modulates angiotensin IIinduced fibrosis in the intact murine heart. J.Am.Coll.Cardiol. 43, 1698-1705 (2004)
70. Y. Matsui, N. Jia, H. Okamoto, S. Kon, H. Onozuka, M. Akino, L. Liu, J. Morimoto, S. R. Rittling, D. T. Denhardt, A. Kitabatake & T. Uede: Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43, 1195-1201 (2004)
71. F. Sam, Z. Xie, H. Ooi, D. L. Kerstetter, W. S. Colucci, M. Singh & K. Singh: Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am.J.Hypertens. 17, 188-193 (2004)
72. H. E. Kirn, S. S. Dalai, E. Young, M. J. Legato, M. L. Weisfeldt & J. D'Armiento: Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J.Clin.Invest 106, 857-866 (2000)